Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-miR-23b
- Development stage
- Preclinical
- Lead developer
- Tianjin Medical University General Hospital
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
AS-miR-23b is an antisense oligonucleotide (ASO) designed to target and silence microRNA-23b (miR-23b), an oncomiR that is frequently overexpressed in glioblastoma and other gliomas. By binding to miR-23b, the ASO prevents the microRNA from suppressing its direct target, the Von Hippel-Lindau (VHL) tumor suppressor gene. Restoration of VHL levels leads to the degradation of hypoxia-inducible factor 1-alpha (HIF-1α) and the inhibition of the β-catenin/Tcf-4 transcriptional activity. Preclinical studies have demonstrated that treatment with AS-miR-23b reduces glioma cell survival, induces apoptosis, and suppresses tumor cell invasion and angiogenesis.
- Other names
- antisense miR-23banti-miR-23banti-miR23banti-miR 23bmiR-23b inhibitormiR23b inhibitormiR 23b inhibitor
Beyond the preview
Go deeper on AS-miR-23b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS-miR-23b.